Can Atropos Health transform the landscape of evidence based medicine with technology?

By Liza Laws

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Technology Clinical trials Data management Research Real world data electronic medical records

In order to find out, OSP sat down with Brigham Hyde to ask him a number of questions about the company's technology and what it is doing to upgrade traditional trial methods.

LL: Before we delve into the specifics of your work at Atropos Health, could you provide a bit more background about yourself and your involvement in tech-enabled trials?

BH:​ Certainly. I'm the CEO and co-founder of Atropos Health. My journey into the realm of health tech and data sciences began during my tenure at Stanford University about three years ago. Prior to that, I've had a rich background in analytics and health economics, spanning over 15 years in various capacities across different healthcare sectors, including providers and payers. My academic pursuits led me to obtain a PhD in Clinical Pharmacology, laying the foundation for my transition from bench clinical research to pioneering health economic data businesses. We use cutting-edge technology to transform traditional clinical trial methodologies, thereby revolutionizing the landscape of evidence-based medicine.

LL: Let's dive straight into a pressing issue: the lack of diversity in clinical trials and its implications for health equity. How does this shortfall contribute to widening health disparities and delaying equitable access to medications and treatments?

BH:​ The lack of diversity in clinical trials is indeed a critical issue with far-reaching consequences. Traditional trials often fail to represent the broader patient population, either due to exclusion criteria or inadequate recruitment strategies. This leads to a skewed understanding of drug efficacy and safety across different demographic groups, exacerbating health disparities and impeding equitable access to care. We address this challenge head-on by harnessing real-world data to recreate trials in more diverse patient cohorts. By doing so, we can provide clinicians with evidence tailored to their patients' profiles, ensuring that treatment decisions are grounded in comprehensive data that reflects the diversity of the population.

LL: Your approach to using real-world data to bridge the evidence gap is interesting. Could you elaborate on how Atropos Health's technology facilitates this process and expedites the generation of actionable insights for clinicians?

BH:​ Absolutely. We've developed proprietary technology that enables us to leverage real-world data from electronic medical records (EMRs) to conduct rapid and robust observational studies. This technology allows us to recreate clinical trials in diverse patient populations with unparalleled speed and accuracy. Clinicians can simply submit their queries, and within a day, we deliver publication-grade research studies tailored to their specific patient demographics and clinical scenarios. By automating and streamlining this process, we empower clinicians to make informed care decisions based on robust evidence that aligns with their patients' needs and characteristics.

LL: It's remarkable how Atropos Health is revolutionizing evidence-based medicine through technology-driven solutions. Moving forward, how do you envision your approach positively impacting marginalized populations and driving more inclusive healthcare outcomes?

BH:​ Our approach holds tremendous potential for positively impacting marginalized populations in several ways. Firstly, by ensuring that clinical evidence reflects the diversity of patient demographics, we can identify treatment strategies that are most effective across different population groups. This, in turn, facilitates more personalized and culturally sensitive care, ultimately leading to better health outcomes for marginalized communities. Additionally, our technology has the capacity to inform the design of more inclusive clinical trials, thereby expanding access to cutting-edge treatments for historically underserved populations. By democratizing access to high-quality evidence and promoting diversity in research, we can work towards achieving health equity and mitigating disparities in healthcare delivery.


LL: You are committed to advancing health equity through innovative tech. As we navigate the evolving landscape of evidence-based medicine, what challenges do you anticipate, and how do you plan to address them?

BH: While our approach holds immense promise, we recognize that there are challenges inherent in leveraging real-world data for evidence generation. One significant challenge pertains to data quality and interoperability, as disparate EMR systems may vary in their completeness and accuracy. To address this, we've implemented rigorous data validation processes and developed advanced analytics tools to ensure the reliability and integrity of our findings. Additionally, regulatory considerations pose another hurdle, particularly regarding the acceptance of real-world evidence by regulatory agencies. However, we're actively engaged in dialogue with regulatory authorities to demonstrate the validity and utility of our approach, thereby paving the way for broader acceptance and integration of real-world data into regulatory decision-making processes.

LL: Your proactive approach to overcoming challenges and driving regulatory acceptance seems essential for the widespread adoption of innovative evidence-generation methodologies. Looking ahead, what do you envision as the future of evidence-based medicine, particularly in light of emerging technologies and regulatory frameworks?

BH: The future of evidence-based medicine holds immense promise, fueled by advances in technology and evolving regulatory frameworks. I foresee a paradigm shift towards a more holistic and patient-centric approach to evidence generation, wherein real-world data plays a central role in complementing traditional clinical trials. As regulatory agencies embrace the potential of real-world evidence, we'll witness greater integration of diverse data sources into decision-making processes, enabling more tailored and inclusive healthcare interventions. Moreover, emerging technologies such as artificial intelligence and machine learning will further enhance our ability to extract meaningful insights from complex datasets, driving continuous innovation in evidence generation and healthcare delivery. Ultimately, by leveraging technology, collaboration, and a commitment to diversity, we can usher in a new era of evidence-based medicine that prioritizes equity, accessibility, and patient empowerment.

LL: Your insights into the future of evidence-based medicine are very positive. Before we conclude, do you have any final thoughts or reflections you'd like to share?

BH:  I'd like to express my gratitude for the opportunity to share our work and vision with your audience. We're driven by a shared commitment to advancing healthcare equity and improving patient outcomes. As we continue on this journey, I encourage stakeholders across the healthcare ecosystem to embrace innovation, collaboration, and inclusivity in pursuit of our shared goal: to ensure that every patient receives the care they deserve. Together, we can harness the power of technology and evidence-based medicine to transform lives and build a healthier, more equitable future for all.

I'm excited to see the transformative impact of evidence-based medicine unfold, and I'm confident that together, we can shape a brighter future for healthcare worldwide.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us


View more